Review
Copyright ©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 125-134
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125
Figure 14
Figure 14 Phase III trial of paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. Progression-free survival (PFS) (median, 11.8 mo vs 5.9 mo, hazard ratio = 0.60). (Source: Figure 2A in reference 21).